Difference between revisions of "Part:BBa K4156119"

 
Line 3: Line 3:
 
<partinfo>BBa_K4156119 short</partinfo>
 
<partinfo>BBa_K4156119 short</partinfo>
  
−
To be refined
+
XOR gate-HlyE consists of an XOR logic gate (<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156117"> BBa_K4156117 </a></html>) and a downstream HlyE (<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156084"> BBa_K4156084 </a></html>) sequence, and tests the performance of the XOR gate by detecting the red fluorescent signal.
 +
 
 +
<!-- Add more about the biology of this part here -->
  
−
<!-- Add more about the biology of this part here
 
 
===Usage and Biology===
 
===Usage and Biology===
  
−
<!-- -->
+
The construction of this part is similar to XOR gate-mRFP (<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156124"> BBa_K4156124 </a></html>). The difference is that we replaced the mRFP protein with the HlyE therapeutic protein. This is to verify the therapeutic power of the recombinant strain under XOR gate control. After co-incubation of the recombinant strain with cancer cells, cell viability was monitored using the CCK8 assay to assess the therapeutic power of the recombinant strain and the reinforcing effect of the XOR gate.
 +
 
 +
 
 
<span class='h3bb'>Sequence and Features</span>
 
<span class='h3bb'>Sequence and Features</span>
 
<partinfo>BBa_K4156119 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K4156119 SequenceAndFeatures</partinfo>

Revision as of 07:36, 9 October 2022


XOR gate-HlyE

XOR gate-HlyE consists of an XOR logic gate ( BBa_K4156117 ) and a downstream HlyE ( BBa_K4156084 ) sequence, and tests the performance of the XOR gate by detecting the red fluorescent signal.


Usage and Biology

The construction of this part is similar to XOR gate-mRFP ( BBa_K4156124 ). The difference is that we replaced the mRFP protein with the HlyE therapeutic protein. This is to verify the therapeutic power of the recombinant strain under XOR gate control. After co-incubation of the recombinant strain with cancer cells, cell viability was monitored using the CCK8 assay to assess the therapeutic power of the recombinant strain and the reinforcing effect of the XOR gate.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 614
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 104
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI site found at 124
    Illegal BsaI.rc site found at 351